Actively Recruiting
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Led by Sun Yat-sen University · Updated on 2026-05-11
148
Participants Needed
1
Research Sites
203 weeks
Total Duration
On this page
Sponsors
S
Sun Yat-sen University
Lead Sponsor
Z
Zhejiang Cancer Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.
CONDITIONS
Official Title
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with nasopharyngeal carcinoma who have recurred or metastasized after initial or radical treatment
- Age between 18 and 75 years, male or female
- Pathological diagnosis of nasopharyngeal carcinoma
- ECOG performance status of 0 to 1
- No prior anti-tumor treatment for recurrence or metastasis
- No contraindications to chemotherapy, immunotherapy, or targeted therapy
- At least one measurable lesion according to RECIST 1.1 criteria
- Blood counts meeting specified minimum levels without recent transfusions or stimulating factors
- Biochemical tests within defined limits for liver, kidney function, and coagulation
- Normal myocardial enzyme levels
- For women of childbearing age, use of reliable contraception and negative pregnancy test before enrollment; for men, use of effective contraception during and for 3 months after trial
- Voluntary consent with good compliance and willingness to follow up
You will not qualify if you...
- Patients with recurrence suitable for local surgery or radiotherapy
- Known allergy to study drugs or severe reaction to monoclonal antibodies
- Symptoms of central nervous system metastasis requiring hormonal treatment
- Active infection or unexplained fever above 38.5 C during screening or before first dose
- Active or history of autoimmune disease, except some controlled conditions
- Congenital or acquired immunodeficiency, active hepatitis B or C infection
- Other active cancers except certain cured skin, cervical, or bladder cancers
- Uncontrolled heart disease, recent myocardial infarction, or poor heart function
- Incomplete recovery from major surgery before treatment
- Participation in another clinical trial or investigational drug use within 4 weeks
- Live vaccine receipt within 4 weeks prior to study drug administration
- Pregnant or breastfeeding women
- Other serious medical or social conditions that may affect safety or study conduct
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Actively Recruiting
Research Team
Z
Zhao Chong PhD.
CONTACT
M
Miao Jingjing MD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here